Enterprise introduction of Hunan Zhengqing Pharmaceutical Group Co., Ltd.

Hunan Zhengqing Pharmaceutical Group Co., Ltd. was established in 1992, with total assets of 456 million yuan, net assets of 350 million yuan and employees of 1200. The holding and shareholding enterprises of the Group include Huaihua Zheng Hao Pharmaceutical Co., Ltd., Hunan Zhengchi Pharmaceutical Co., Ltd., Hunan Jacky Biological Resources Development Co., Ltd. and Huaihua Automobile Training Third School. Dr. Wu Feichi, founder and chairman of Zhengqing Group, is a representative of Hunan Provincial People's Congress, a winner of the National May 1 Labor Medal, and an expert enjoying special government allowance from the State Council. Under his leadership, Zhengqing Group has developed from an initial workshop-style small pharmaceutical factory into one of the top ten high-tech enterprises in Hunan Province, a national high-tech demonstration enterprise for modernization of traditional Chinese medicine, and a national key leading enterprise for agricultural industrialization. With a postdoctoral research center, it is the first enterprise specializing in spectral efficiency research of Houttuynia cordata Thunb in China, and one of the key high-tech enterprises and four major pharmaceutical enterprises in Hunan Province. As one of the most comprehensive pharmaceutical companies in China that have passed GMP dosage forms, Zhengqing is committed to building five product series according to the product combination model of "3+ 1+n": an anti-rheumatic drug series represented by Zhengqing Fengtongning sustained-release tablets, the first patented Chinese medicine in China; Traditional Chinese medicine injection series represented by Boshicao TM Houttuynia injection; He Zhengqing? Ganoderma lucidum series represented by Ganoderma lucidum oral liquid; Zuo Fuxin? Western medicine series represented by levofloxacin hydrochloride; He Zhengqing? Characteristic drug series represented by sibutramine hydrochloride tablets. Zhengqing has always insisted on independent innovation as the driving force to improve the core competitiveness of enterprises. Relying on independent innovation, Zhengqing brand has been cultivated in the fierce market competition, a stable market network has been established, and remarkable economic and social benefits have been achieved. The total assets expanded from 4.7 million yuan to 456 million yuan, and the enterprise achieved extraordinary development. He has applied for 35 national patents, including 24 invention patents, and developed more than 30 national new drugs, such as Zhengqingfengtongning, Ganoderma lucidum oral liquid and Boshicao. There are more than 300 approvals for pharmaceutical production, of which 69% are independent innovation and 27% are domestic leading level. Zhengqing has also established a scientific and technological system with provincial enterprise technology center as the core, postdoctoral research center and traditional Chinese medicine spectrum efficiency engineering technology research center as the support, and domestic scientific research institutes and industry experts as the support. Seven products, including Zhengqingfengtongning tablets, developed by the company were listed as national protected varieties of traditional Chinese medicine by the Ministry of Health, and the project of "Qingfengteng Modern Series Preparations" was rated as a high-tech industrialization demonstration project by the National Development and Reform Commission, while Zhengqingfengtongning sustained-release tablets and Yuqing Kanggongyan tablets were rated as national key new products. Zhengqingfengtongning sustained-release tablets won the title of outstanding technological innovation project in Hunan Province, and sinomenine sustained-release preparation and preparation method won the outstanding patent award in Hunan Province in 2005. Zhengqing adheres to the business philosophy of "man is God and competition is life" and has been pursuing a harmonious life with customers, shareholders and society. The corporate culture book "The Invisible Hand-The Theory of Corporate Life" written by Dr. Wu Feichi, Chairman of the Board of Directors, has aroused strong repercussions in the business, academic and press circles. Zhengqing advocated the creation of "Xiangxi Traditional Chinese Medicine Valley" featuring the industrialized management and innovation of traditional Chinese medicine, which was listed as a key project for the development of Xiangxi by Hunan Province.